Business Context and Reporting Period
Company: nLIGHT, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: February 3, 2026
Event: Entry into an underwriting agreement for an underwritten public offering of common stock.
Key Financial Metrics
This filing reports on a capital raise event rather than operational financial performance. Key metrics related to the offering include:
- Shares Offered: 3,977,273 shares of common stock.
- Public Offering Price: $44.00 per share.
- Price to Company: $42.02 per share.
- Expected Net Proceeds: Approximately $166.5 million.
- Over-Allotment Option: Underwriters have a 30-day option to purchase up to 596,590 additional shares.
- Maximum Potential Proceeds: Approximately $191.5 million if the over-allotment option is exercised in full.
Note: The filing text does not provide current revenue, profit, cash flow, margins, debt, or liquidity figures.
Material Changes
The primary material change is the execution of the Underwriting Agreement, which will result in a significant increase in the company's cash position upon closing. The company has granted underwriters a 30-day option to purchase additional shares, potentially increasing the total capital raised by approximately $25 million.
Guidance, Outlook, and Risks
- Use of Proceeds: The company intends to use net proceeds for working capital, capital expenditures, and other general corporate purposes.
- Closing Date: Expected on or about February 5, 2026, subject to customary closing conditions.
- Lock-Up Agreement: The company and its executive officers and directors have entered into lock-up arrangements prohibiting the sale or transfer of securities for a 60-day period, subject to exceptions.
- Risks: The filing includes standard forward-looking statement disclaimers. Risks include uncertainties related to market conditions and the potential failure to complete the public offering on anticipated terms.
Investor Verification Checklist
- Verify the final closing date of the offering (expected February 5, 2026).
- Confirm whether the underwriters exercise the 30-day over-allotment option for an additional 596,590 shares.
- Review the final prospectus supplement for detailed risk factors and specific allocation of capital expenditures.
- Monitor the company's cash balance post-closing to assess the impact on liquidity.